On March 4, 2020 Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3 platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, reported the appointment of Dr. May Orfali to the position of Consultant Chief Medical Officer, effective immediately (Press release, biOasis, MAR 4, 2020, View Source [SID1234555185]). In this position, Dr. Orfali replaces Dr. Jose Iglesias, who has recently accepted a full-time position at another company. We thank Dr. Iglesias for his contributions to Bioasis to date.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. May Orfali has a deep and extensive background in drug and clinical development programs that spans two decades in multiple therapeutic areas, with a focus on rare diseases, oncology, hematology, infectious disease and women’s health. Her most recent role was President at Oncology and Rare disease Consulting, LLC, she was the Chief Medical Officer at CANbridge Life Sciences where she led the clinical development and medical affairs group, focused on progressing phase 1 and phase II oncology assets in glioblastoma multiforme and esophageal cancer, filing NDA for neratinib in China in adjuvant and metastatic breast cancer therapy. Dr. Orfali has also spent several years at Pfizer as Global Medical Lead and Executive Director, Global Product Development across multiple rare disease assets in hematology, sickle cell disease, hemophilia, endocrinology, gene therapy and TTR-amyloidosis. Prior to her time at Pfizer, Dr. Orfali held several clinical leadership positions, at Wyeth, Artisan Pharma, Aeris Therapeutics, Cubist Pharmaceuticals and Boston Scientific Corporation.
Dr. Orfali holds a medical degree from the University of Baghdad, Baghdad, Iraq, and a Pharmaceutical Master of Business Administration from Cambridge University, Cambridge, England. She was a practicing physician, specialized in CNS Oncology Clinical Research at Dana-Farber Cancer Institute, in Boston, MA and completed her Fellowship in Pediatric Oncology/Hematology at Massachusetts General Hospital and Children’s Hospital, Boston, MA.
"We are very pleased that Dr. Orfali has joined the team at Bioasis. She has a unique experience in clinical development that is well suited to Bioasis’ deep pipeline across multiple therapeutic areas including neuro-oncology and rare diseases," said Deborah Rathjen, Bioasis’ CEO and Chair. "In particular Dr. Orfali will make a significant contribution to the progression of our lead program xB3-001 in development for the treatment of Her2+ breast cancer and brain metastases. We are very appreciative of the contribution Jose has made to this important program and we wish him all the best," Deborah Rathjen added.
"The promise offered by Bioasis’ technology platform has the potential to make a real difference in the life of Her2+ breast cancer patients with brain metastases. This condition is very hard to treat, and efficient solutions are needed for it. I am thrilled to be part of this exciting endeavor," said Dr. May Orfali.